Ontology highlight
ABSTRACT:
SUBMITTER: Cordek DG
PROVIDER: S-EPMC3558953 | biostudies-literature | 2011 Sep
REPOSITORIES: biostudies-literature
Cordek D G DG Bechtel J T JT Maynard A T AT Kazmierski W M WM Cameron C E CE
Drugs of the future 20110901 9
Hepatitis C virus (HCV) infects more than 3% of the world's population, leading to an increased risk of cirrhosis and hepatocellular carcinoma. The current standard of care, a combination of pegylated interferon alfa and ribavirin, is poorly tolerated and often ineffective against the most prevalent genotype of the virus, genotype 1. The very recent approval of boceprevir and telaprevir, two HCV protease inhibitors, promises to significantly improve treatment options and outcomes. In addition to ...[more]